

# Comparative Efficacy of Different Classes of Antiemetic Medications for the Prevention of Nausea and Vomiting in Cesarean Section: A Network Meta-Analysis

## Abstract

**Background:** Antiemetic medications have been associated with the prevention of nausea and vomiting in cesarean section, although less is known about the comparative efficacy of different medication classes. **Methods:** We conducted a systematic review with network meta-analyses to compare and rank antiemetic medication classes (5-HT<sub>3</sub> receptor antagonists, dopamine receptor antagonists, corticosteroids, antihistamines, anticholinergic agents, sedatives, and opioid antagonists or partial agonists) in terms of preventing intra- and postoperative nausea and vomiting among patients undergoing cesarean section. We included all randomized controlled trials (RCTs) that evaluated any antiemetic medication classes' treatment for target outcomes. Network meta-analysis was conducted with a frequentist approach using the R *netmeta* package. A total of 58 trials were included (6,665 women undergoing cesarean section; mean age, 28.1 years). **Results:** Compared with placebo, all interventions reduced the odds of intraoperative nausea (except antihistamines), intraoperative vomiting (except antihistamines), postoperative nausea (except anticholinergic agents and opioid antagonists), and postoperative vomiting (except opioid antagonists). In terms of intraoperative nausea and both intra- and postoperative vomiting, sedatives ranked first among other medication classes. **Conclusions:** The relative effect sizes for various classes of antiemetic medication in preventing nausea and vomiting in the cesarean section were modeled using the principles of network meta-analysis which may facilitate informed clinical decision-making.

**Keywords:** *Antiemetics, cesarean section, nausea and vomiting, network meta-analysis*

## Introduction

Cesarean section is one of the most frequent surgical procedures performed, comprising about 7% of surgeries worldwide.<sup>[1]</sup> Despite remarkable advances in different anesthesia techniques,<sup>[2]</sup> intra- and postoperative nausea and vomiting are still present in a significant number of patients. It is estimated that up to 80% of patients undergoing cesarean section experience nausea and vomiting during and/or after the procedure.<sup>[3]</sup>

The negative impacts of nausea and vomiting in such surgeries are well-recognized. It can be disturbing and unpleasant to patients and make surgery difficult. In addition, it can complicate the postoperative course in several ways—(i) vomit aspiration, (ii) disturbance of electrolyte and dehydration, (iii) delay in nutrition and fluid intake and oral drug therapy, and (iv) wound dehiscence.<sup>[4,5]</sup> Moreover,

surgery-related nausea and vomiting can result in prolonged or unexpected hospital stays or readmission.<sup>[6]</sup>

In response to these challenges, it is important for patients undergoing surgery to be provided with sufficient antiemetic prophylaxis.<sup>[7]</sup> A broad variety of antiemetic medications are available for the prevention of nausea and vomiting among patients undergoing different kinds of surgeries.<sup>[4]</sup> Many studies have evaluated the effects of the available antiemetics to reduce the likelihood of developing nausea and vomiting in cesarean section procedures.

However, the existent trials investigated different ranges of pharmacological interventions in various ways, creating a wide spectrum of information about their efficacy that is difficult to assess through simple direct comparisons.<sup>[8]</sup> The lack of

Zoleykha Asgarlou,  
Elham  
Dehghanpour  
Mohammadian<sup>1</sup>,  
Sousan  
Houshmandi<sup>2</sup>,  
Mohammad  
Mohseni<sup>3</sup>,  
Sepideh Gareh  
Sheyklo<sup>4</sup>,  
Ahmad Moosavi<sup>5</sup>,  
Shiler Ahmadi<sup>6</sup>

*Department of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran, <sup>1</sup>Department of Midwifery, Faculty of Nursing and Midwifery, Islamic Azad University, Zanjan Branch, Zanjan, Iran, <sup>2</sup>Department of Midwifery, School of Nursing and Midwifery, Ardabil University of Medical Sciences, Ardabil, Iran, <sup>3</sup>Department of Health Services Management, School of Management and Medical Information Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, <sup>4</sup>Department of Obstetrics and Gynecology, Dezful University of Medical Sciences, Dezful, Iran, <sup>5</sup>Department of Health and Community Medicine, Dezful University of Medical Sciences, Dezful, Iran, <sup>6</sup>Department of Nursing and Midwifery, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran*

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Asgarlou Z, Mohammadian ED, Houshmandi S, Mohseni M, Sheyklo SG, Moosavi A, et al. Comparative efficacy of different classes of antiemetic medications for the prevention of nausea and vomiting in cesarean section: A network meta-analysis. *Int J Prev Med* 2023;14:116.

### Access this article online

**Website:**  
[www.ijpvmjournal.net/www.ijpvm.ir](http://www.ijpvmjournal.net/www.ijpvm.ir)

**DOI:**  
10.4103/ijpvm.ijpvm\_250\_22

### Quick Response Code:



**Address for correspondence:**

Dr. Shiler Ahmadi,

Department of Nursing and Midwifery, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran.

E-mail: ahmadi.sh64@gmail.com

head-to-head comparisons of various pharmacological interventions renders the choice of treatment a clinical challenge. Therefore, we conducted a network meta-analysis that provided direct, indirect, and mixed evidence<sup>[9]</sup> to compare multiple medication classes simultaneously regarding their efficacy in terms of preventing nausea and vomiting in cesarean section.

**Methods**

We conducted our systematic review in accordance with the PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Healthcare Interventions.<sup>[10]</sup>

**Search strategy**

The search strategy was developed in collaboration with a research librarian. Several relevant databases were searched, including Cochrane Central Register of Controlled Trials, CINAHL, Embase, and MEDLINE, from the date of their inception to October 31, 2021 (final search), with no language restrictions. We searched for RCTs on the use of antiemetic medications for nausea and vomiting among women undergoing cesarean section. The initial search was developed in MEDLINE [Supplementary Table 1] and adjusted to other databases. The electronic database searches were supplemented with a manual search of reference lists of all eligible articles as well as relevant reviews.

**Eligibility criteria**

**Types of studies:** We included randomized controlled trials (RCTs) of antiemetic drugs in the treatment of nausea and vomiting among patients undergoing cesarean section. We did not restrict the study eligibility by publication status or language. Prospective cohort studies and quasi-randomized studies were excluded.

**Types of participants:** We included pregnant females undergoing elective or emergency cesarean section under regional anesthesia.

**Types of interventions:** In this systematic review, we included studies that participants were females undergoing cesarean section under regional anesthesia (either spinal, epidural, or both) comparing pharmacological interventions for preventing nausea and vomiting against placebo or each other (intervention versus intervention comparisons). We set no restrictions on the drug doses or when treatments were applied (either intraoperatively, postoperatively, or both). In this systematic review, we focused on studies where interventions were given with the specific purpose of preventing nausea and/or vomiting.

Thus, interventions of interest were the following drug classifications: (a) serotonin (5-HT<sub>3</sub>) receptor antagonists, (b) dopamine receptor antagonists, (c) corticosteroids, (d) antihistamines, (e) anticholinergic agents, (f) sedatives, and (g) opioid antagonists or partial agonists.

We excluded studies in which the focus was on non-pharmacological interventions. We also excluded trials with the express purpose of investigating the effects of drugs on other clinical conditions such as aspiration pneumonitis. Studies that investigated the efficacy of interventions for alleviating established nausea and vomiting were also excluded.

**Types of outcomes:** The primary outcomes of this network meta-analysis were the incidence of nausea and vomiting categorized as follows:

1. Intraoperative nausea
2. Intraoperative vomiting
3. Postoperative nausea
4. Postoperative vomiting

We excluded studies that did not provide separate data on nausea or vomiting and presented a combined score. We also excluded studies that reported the number of nausea and vomiting episodes, rather than the number of pregnant women who had nausea and/or vomiting.

**Study selection and data extraction**

Two investigators screened titles and abstracts of citations in duplicate and independently. All records judged potentially relevant were evaluated for full-text eligibility by the same two reviewers. Discordances were discussed with a third reviewer and resolved by consensus. We extracted data on study characteristics including first author, publication year, study settings (country), the mean age of participants, anesthesia type, mean operation duration, intervention characteristics, and outcome data using a structured extraction form (Microsoft Access, 2020).

**Risk of bias assessment**

The methodological quality of included studies was independently evaluated by two of the reviewers using the Cochrane Collaboration's tool for assessing the risk of bias.<sup>[11]</sup> Trials were judged as having a "low," "high," or "unclear" risk of bias across the seven specified domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias.

## Statistical analysis

The network meta-analysis was concocted using the R *netmeta* package,<sup>[12]</sup> applying a frequentist approach.<sup>[13]</sup> The *netgraph* function was used to generate network plots to describe and present the geometry of different forms of interventions. Nodes were used to represent different medication classes and edges to represent the head-to-head comparisons between interventions. Random effect models were employed because of the between-study heterogeneities. We assessed between-study heterogeneities using Cochran Q (weighted sum of squared differences between individual study effects and the pooled effect across studies) and I<sup>2</sup> (percentage of variation across studies due to heterogeneity rather than chance).

We calculated treatment estimates for all outcomes as odds ratios (ORs), together with their 95% confidence intervals (CIs). The relative ranking probability of each pharmacological intervention being among the best intervention was obtained using *P*-score and displayed using a netrank plot.<sup>[14]</sup> A higher *P*-score meant better treatment. A node-splitting method was used to split network estimates into the contribution of direct and indirect evidence and to test for local inconsistency in network meta-analysis. To assess the global inconsistency in each model, we used *decomp.design* function. A *P* value < 0.005 was considered suggestive of significant inconsistency. Publication bias was assessed using comparison-adjusted funnel plots. *P* values < 0.005 indicated a significant difference.

## Results

We identified a total of 1,613 potentially relevant records through database searching in addition to 25 records retrieved by manual citation search. The results of the literature search and selection process are shown in the PRISMA flowchart [Figure 1].

### Characteristics of included studies

A total of 58 RCTs,<sup>[15-69]</sup> comprising 6,665 randomized pregnant women, were mostly of small size with a median (IQR [range]) number of 90 (67–149 [40–300]) participants, with a median age of 28.1 years (IQR: 26.3–30.2) and published between 1987 and 2020 (with 80% from 2000 onward). The included studies emanated from 18 separate countries and most of them were from the USA (11 studies), followed by Iran (8 studies) and India (6 studies). In this review, 14 single antiemetic medications under seven classifications were included. Most trials investigated only a single drug (38 studies), and the remaining 20 studies were multi-arm trials with more than one medication agent [Supplementary Table 2].

The risk of bias summary is provided in Figure 2. Of the 55 studies, many were deemed to be of unclear or high risk of bias in three domains as follows: allocation concealment (*n* = 50 [90%]), blinding (*n* = 31 [56%]), and selective reporting (*n* = 55 [100%]). The risk of bias for each study is shown in Supplementary Figure 1

### Assessment of publication bias

Comparison-adjusted funnel plots [Figure 3] were symmetrical, implying evidence of publication bias.




Figure 1: Study selection for the meta-analysis

### Intraoperative nausea

Figure 4 shows the network of eligible comparisons for intraoperative nausea, including 38 RCTs with 4,100 pregnant women and six antiemetic medication classes, and a placebo. Dopamine receptor antagonists ( $n = 15$  studies), 5-HT3 receptor antagonists ( $n = 12$  studies), and sedatives ( $n = 8$  studies), all compared with placebo, were the most common comparisons.

Of the six included pharmacological interventions, five medication classes had significantly greater effects on intraoperative nausea compared with placebo as follows: dopamine receptor antagonists (OR = 0.27, 95% CI: 0.19–0.40), 5-HT3 receptor antagonists (OR = 0.32, 95% CI: 0.23–0.44), anticholinergic agents (OR = 0.33, 95% CI: 0.19–0.57), and sedatives (OR = 0.44, 95% CI: 0.28–0.70) [Figure 5]. According to the  $P$ -score for the prevention of intraoperative nausea, dopamine receptor antagonists were ranked the best among all treatments [Figure 5].

### Intraoperative vomiting

Among the eligible trials considered in this review, 34 studies, involving 3,857 patients, reported data on intraoperative vomiting. The network of eligible comparisons for this outcome is shown in Figure 4. Dopamine receptor antagonists ( $n = 12$ ), 5-HT3 receptor antagonists ( $n = 11$ ), and sedatives ( $n = 8$ ), all compared with the placebo, were the most common comparisons.

Figure 5 shows the effects of intraoperative vomiting between active pharmacological interventions and placebo. This

ranking plot demonstrated that sedatives (OR = 0.25, 95% CI: 0.15–0.41), dopamine receptor antagonists (OR = 0.34, 95% CI: 0.21–0.54), 5-HT3 receptor antagonists (OR = 0.35, 95% CI: 0.24–0.51), corticosteroids (OR = 0.44, 95% CI: 0.24–0.82), and anticholinergic agents (OR = 0.49, 95% CI: 0.28–0.87) were significantly more efficacious than the placebo. According to the rank-heat plot, sedatives were the most effective pharmacological interventions for preventing early intraoperative vomiting [Figure 5].

### Postoperative nausea

For estimating the drug efficacy against postoperative nausea, we looked at data from 3,251 individuals from 26 studies. The network diagram [Figure 4] presents direct comparisons among classes. 5-HT3 receptor ( $n = 10$ ), dopamine receptor antagonists ( $n = 7$ ), and corticosteroids ( $n = 6$ ), all compared with placebo, were the most common comparisons.

Figure 5 provides the network meta-analysis results with the ranking of all medication classes compared with placebo for intraoperative nausea. This ranking showed that sedatives (OR = 0.17, 95% CI: 0.07–0.40), antihistamines (OR = 0.25, 95% CI: 0.13–0.48), 5-HT3 antagonists (OR = 0.25, 95% CI: 0.17–0.39), corticosteroids (OR = 0.35, 95% CI: 0.21–0.60), and dopamine receptor antagonists (OR = 0.45, 95% CI: 0.26–0.75) were significantly superior for placebo in preventing intraoperative nausea. Two other antiemetics (i.e., anticholinergic agents and opioid antagonists) showed no significant beneficial effect compared with a placebo.




Figure 2: Risk of bias summary




Figure 3: Comparison-adjusted funnel plots of trials included in the network meta-analysis for each outcome




Figure 4: Network diagram representing direct comparisons among medication classes. The width of lines indicates the number of trials in which each direct comparison is made




Figure 5: Treatment efficacy in the prevention of nausea and vomiting among patients undergoing cesarean section. Heterogeneity statistics: intraoperative nausea ( $I^2$ : 40.2,  $Q$  = 51.9); intraoperative vomiting ( $I^2$ : 23.0,  $Q$  = 49.8); postoperative nausea ( $I^2$ : 51.8.2,  $Q$  = 53.9); postoperative vomiting ( $I^2$ : 47.2,  $Q$  = 34.9)

The rank-heat plot of treatments [Figure 5] showed that sedatives had the most preventive effect among other medication classes in terms of postoperative nausea.

### Postoperative vomiting

Twenty-eight trials were included in the network meta-analysis for postoperative vomiting, with 3,608 pregnant women and seven interventions (6 drug classes and placebo) [Figure 4]. 5-HT3 receptor antagonists ( $n$  = 10 studies), dopamine receptor antagonists ( $n$  = 9 studies), and corticosteroids ( $n$  = 7 studies), all compared with placebo, were the most common comparisons.

For postoperative vomiting, all classes of medications, but opioid antagonists, had significantly beneficial effects compared with the placebo with 46% to 87% relative risk reductions. The specific estimated ORs were as follows: sedatives (OR = 0.13, 95% CI: 0.05–0.37), antihistamines (OR = 0.23, 95% CI: 0.09–0.59), 5-HT3 antagonists (OR = 0.29, 95% CI: 0.17–0.49), anticholinergic agents (OR = 0.29, 95% CI: 0.10–0.84), dopamine receptor antagonists (OR = 0.52, 95% CI: 0.32–0.85), and corticosteroids (OR = 0.54, 95% CI: 0.31–0.94). Opioid antagonists showed no significant beneficial effect compared with the placebo [Figure 5]. According to the  $P$ -score plot, of all medication classes, sedatives were ranked first for the prevention of postoperative vomiting [Figure 6].

### Heterogeneity and consistency analysis

The evaluation of inconsistency in the contribution of direct and indirect evidence using a node-splitting method showed that there were no inconsistencies among almost all studies ( $P$  > 0.05). In addition, the results of the decomp.design function supported the global consistency for all models, indicating the reliability of the results [Supplementary Tables 3 and 4].

### Discussion

Although several systematic reviews on pharmacological interventions for the prevention of post-cesarean nausea and vomiting have been performed,<sup>[70,71]</sup> they were conducted using traditional meta-analysis. In contrast, we have used network meta-analysis to evaluate the evidence for medication classes' efficacy in preventing these outcomes. Unlike conventional meta-analysis, where only two interventions are compared by applying pooled head-to-head data, network meta-analysis allows not only for comparisons between multiple interventions but also for comparisons between interventions that have not been compared directly in RCTs.<sup>[72]</sup> These advantages allow clinicians to reach informed treatment decisions based on evidence from network meta-analysis, specifically in the absence of direct comparison of candidate treatments. In this systematic review, we included all antiemetic options for investigating their effect on the prevention of post-cesarean nausea and vomiting.

This network meta-analysis indicates that most of the antiemetic pharmacological classes were statistically superior to placebo in terms of nausea and vomiting among women undergoing cesarean section. For example, In a study conducted by Tkachenko and Pyasetska in 2019, it was found that the addition of 4 mg intrathecal dexamethasone as an adjuvant for spinal anesthesia in the elective cesarean section can significantly decrease the frequency and manifestations of nausea.<sup>[23]</sup> In another study, 3 mg (3 ml) of Granisetron was injected after intrathecal injection. The results of this study showed that Granisetron is an effective way to prevent shivering, nausea, and vomiting during cesarean delivery under spinal anesthesia with no effect on the Apgar score.<sup>[39]</sup> However, some investigations showed no significant difference in the number of patients experiencing postoperative nausea and




Figure 6: Results of P-score analysis in terms of each outcome

vomiting between the treatment and control groups.<sup>[26]</sup> Also, the result of the present network meta-analysis is consistent with results from previous conventional meta-analyses,<sup>[70]</sup> and a possible explanation for these results may be the multi-factorial pathogenesis of postoperative nausea and vomiting.<sup>[73]</sup> However, the previous traditional meta-analyses were unable to conclude superiority due to the absence of a direct comparison. In the present network meta-analysis, which included all direct and indirect comparisons, we found that sedatives were significantly better than other medication classes in terms of three of the four selected outcomes, that is, postoperative vomiting, postoperative nausea, and intraoperative vomiting.

The current network meta-analysis showed that different pharmacological classes have different efficacy in terms of nausea and vomiting at different time points (i.e., intraoperatively or postoperatively). These findings further support the idea that drugs with different mechanisms of action (represented as different medication classes in this review) should be used in combination to optimize their efficacy.<sup>[74]</sup>

The included trials showed that emetic symptoms are very common in both intra- and post-cesarean sections. Non-intervention arms of included studies suggested that the prevalence of nausea during cesarean section ranges between 20 and 60% (data not shown). This finding corroborates the recommendations of available guidelines,<sup>[75]</sup> suggesting a focus on the treatment of prophylaxis rather than emesis at cesarean section. After the advantages of a single medication, classes had been established in this

network meta-analysis, and future research needs to move toward combining antiemetics classes for improved efficacy as these kinds of trials are scarce.

### Limitations of the study

This study has limitations that should be considered when interpreting the results. First, most of the included trials in our network meta-analysis had an unclear or high risk of bias for most domains, which decreased this study's overall evidence level. Second, there were potential heterogeneities in patients' characteristics as well as surgical procedures or postoperative care that could have confounded or affected findings for the target outcomes. Third, we could not retrieve additional unpublished reports and are aware that a substantial amount of information is not publicly available. Finally, differences in the time frame outcome evaluation also could not be assessed due to a limited number of studies in certain time frames.

### Conclusion

In conclusion, all topically applied medication classes included in this network meta-analysis were efficacious in terms of most of the targeted outcomes. Sedative agents were highly efficacious in preventing nausea and vomiting among women undergoing cesarean section surgery. However, a similar network meta-analysis is required to rank each treatment option in terms of potential adverse effects.

### Ethical considerations

Ethical issues (including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double

publication and/or submission, redundancy, etc.) have been completely observed by the authors.

### Authors' contributions

ZA and SA contributed to the concept and design of the study. ZA and SH contributed to the analysis and interpretation of the data. EDM, SGS, AM, MM, and SA contributed to the critical revision of the article and writing of the manuscript. All authors reviewed the manuscript.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

**Received:** 22 Jul 22 **Accepted:** 27 Oct 22

**Published:** 28 Sep 23

### References

- Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, *et al.* Size and distribution of the global volume of surgery in 2012. *Bull World Health Org* 2016;94:201-9F.
- Doyle DJ, Dahaba AA, LeManach Y. Advances in anesthesia technology are improving patient care, but many challenges remain. *BMC Anesthesiol* 2018;18:39.
- Jelting Y, Klein C, Harlander T, Eberhart L, Roewer N, Kranke P. Preventing nausea and vomiting in women undergoing regional anesthesia for cesarean section: Challenges and solutions. *Local Reg Anesth* 2017;10:83-90.
- Cao X, White PF, Ma H. An update on the management of postoperative nausea and vomiting. *J Anesth* 2017;31:617-26.
- Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, *et al.* Fourth consensus guidelines for the management of postoperative nausea and vomiting. *Anesth Analg* 2019;131:411-48.
- Kranke P, Eberhart LH. Possibilities and limitations in the pharmacological management of postoperative nausea and vomiting. *Eur J Anaesthesiol* 2011;28:758-65.
- Chatterjee S, Rudra A, Sengupta S. Current concepts in the management of postoperative nausea and vomiting. *Anesthesiol Res Pract* 2011;2011:748031.
- Rouse B, Chaimani A, Li T. Network meta-analysis: An introduction for clinicians. *Intern Emerg Med* 2017;12:103-11.
- Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. *Ann Intern Med* 2013;159:130-7.
- Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, *et al.* The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. *Ann Intern Med* 2015;162:777-84.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- Titaley CR, Hunter CL, Heywood P, Dibley MJ. Why don't some women attend antenatal and postnatal care services?: A qualitative study of community members' perspectives in Garut, Sukabumi and Ciamis districts of West Java Province, Indonesia. *BMC Pregnancy Childbirth* 2010;10:61.
- Rücker G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods* 2012;3:312-24.
- Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Med Res Methodol* 2015;15:58.
- Jain R, Sharma R. A comparative study of effects of glycopyrrolate and ondansetron on nausea and vomiting in cesarean section under spinal anesthesia. *Anesth, Essays Res* 2015;9:348-52.
- Jabalamei M, Honarmand A, Safavi M, Chitsaz M. Treatment of postoperative nausea and vomiting after spinal anesthesia for cesarean delivery: A randomized, double-blinded comparison of midazolam, ondansetron, and a combination. *Adv Biomed Res* 2012;1:2.
- Wu J, Lo Y, Chia Y, Liu K, Fong W, Yang L, *et al.* Prevention of postoperative nausea and vomiting after intrathecal morphine for Cesarean section: A randomized comparison of dexamethasone, droperidol, and a combination. *Int J Obstet Anesth* 2007;16:122-7.
- Wang J-J, Ho S-T, Wong C-S, Tzeng J-I, Liu H-S, Ger L-P. Dexamethasone prophylaxis of nausea and vomiting after epidural morphine for post-Cesarean analgesia. *Can J Anaesth* 2001;48:185-90.
- Voigt M, Fröhlich CW, Hüttel C, Kranke P, Mennen J, Boessneck O, *et al.* Prophylaxis of intra- and postoperative nausea and vomiting in patients during cesarean section in spinal anesthesia. *Med Sci Monit* 2013;19:993-1000.
- Ure D, James K, McNeill M, Booth J. Glycopyrrolate reduces nausea during spinal anaesthesia for caesarean section without affecting neonatal outcome. *Br J Anaesth* 1999;82:277-9.
- Uerpaiojkit K, Chesoh A, Budcharoentong D. Ondansetron for prophylaxis of spinal morphine induced nausea during early rooming in breastfeeding: A randomized placebo controlled trial. *J Med Assoc Thai* 2017;100:1283-9.
- Tzeng J, Wang J, Ho S, Tang C, Liu Y, Lee S. Dexamethasone for prophylaxis of nausea and vomiting after epidural morphine for post-Cesarean section analgesia: Comparison of droperidol and saline. *Br J Anaesth* 2000;85:865-8.
- Tkachenko R, Pyasetska N. The Efficiency of Intrathecal Dexamethasone for Spinal Anaesthesia in Elective Cesarean Section. *BMJ Publishing Group Ltd*; 2019.
- Tarhan Ö, Canbay Ö, Celebi N, Uzun S, Sahin A, Coşkun F, *et al.* Subhypnotic doses of midazolam prevent nausea and vomiting during spinal anesthesia for cesarean section. *Minerva Anesthesiol* 2007;73:629-33.
- Stein DJ, Birmbach DJ, Danzer BI, Kuroda MM, Grunebaum A, Thys DM. Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section. *Anesth Analg* 1997;84:342-5.
- Selzer A, Pryor KO, Tangel V, O'Connell K, Kjaer K. The effect of intravenous dexamethasone on postoperative nausea and vomiting after Cesarean delivery with intrathecal morphine: A randomized-controlled trial. *Can J Anaesth* 2020;67:817-26.
- Sahoo T, SenDasgupta C, Goswami A, Hazra A. Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: A double-blind randomised, placebo-controlled study. *Int J Obstet Anesth* 2012;21:24-8.
- Rudra A, Halder R, Sen A, Kundu S. Efficacy of low dose propofol for control of emetic episodes during caesarean delivery with spinal anaesthesia. *Indian J Anaesth* 2004;48:31-4.
- Rasooli S, Moslemi F, Khaki A. Effect of sub hypnotic doses of propofol and midazolam for nausea and vomiting during spinal anesthesia for cesarean section. *Anesthesiol Pain Med* 2014;4:e19384.
- Peixoto A, Celich M, Zardo L, Peixoto Filho A. Ondansetron



- or droperidol for prophylaxis of nausea and vomiting after intrathecal morphine. *Eur J Anaesthesiol* 2006;23:670-5.
31. Parra-Güiza R, Meléndez HJ, Ochoa ME. Prophylactic efficacy of ondansetron and dexamethasone in nausea and vomit in patients undergoing cesarean section with neuraxial opioids. Controlled clinical trial. *Med UIS* 2018;31:31-8.
  32. Pan A, Rudra A. Prophylactic single dose intravenous administration of ondansetron in the prevention of postoperative emetic symptoms during spinal anaesthesia for caesarean delivery. *Indian J Anaesth* 2003;47:178-80.
  33. Pan P, Moore C, Fragneto R, Ross V, Justis G. Is antiemetic prophylaxis cost-effective for cesarean section patients? *Anesthesiol Philadelphia then Hagerstown* 2000;93(Suppl 2):A1092.
  34. Pan PH, Moore CH. Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. *Anesth Analg* 1996;83:982-6.
  35. Nortcliffe S, Shah J, Buggy D. Prophylaxis of nausea and vomiting after spinal morphine analgesia for caesarean section: Comparison between cyclizine, dexamethasone, and placebo. *Br J Anaesth* 2003;90:665-70.
  36. Munnur U, Tran C, Zambare SN, Lozano-Gorena M, Suresh MS. Post operative nausea and vomiting following cesarean section with intrathecal morphine. *Anesthesiology* 2008;109:A1113.
  37. Mukherjee S, Rudra A, Mandal M, Kumar P. Optimum dose of propofol for prevention of emetic episodes during caesarean delivery: An evaluation. *J Anaesthesiol Clin Pharmacol* 2006;22:139-43.
  38. Mokini Z, Fabbri E, Dell'Atti I, Di Martino R, D'Ettorre M, Petrini F. A randomized, controlled, double blind trial on the incidence of nausea and vomiting with prophylactic subhypnotic propofol vs metoclopramide and in combination therapy in cesarean section with subarachnoid anesthesia: 11AP5-9. *Eur J Anaesthesiol* 2014;31:192.
  39. Mohammadi SS, Jabbarzadeh S, Movafegh A. Efficacy of granisetron on prevention of shivering, nausea and vomiting during cesarean delivery under spinal anesthesia: A randomized double-blinded clinical trial. *J Obstet Anaesth Crit Care* 2015;5:22.
  40. Bolis PF, Guaschino S, Paganelli AM, Sampaolo P. A comparison of droperidol and metoclopramide in the treatment of nausea and vomiting during cis-platinum polichemotherapy in ovarian carcinoma. *Eur J Gynaecol Oncol* 1981;2:57-9.
  41. Mandell GL, Dewan DM, Howard G, Floyd HM. The effectiveness of low dose droperidol in controlling nausea and vomiting during epidural anesthesia for cesarean section. *Int J Obstet Anesth* 1992;1:65-8.
  42. Lussos S, Bader A, Thornhill M, Datta S. The antiemetic efficacy of prophylactic metoclopramide for cesarean delivery. *Anesthesiology* 1991;75:A1080.
  43. Kotelko D, Rottraan R, Wright W, Stone J, Yamashiro A, Rosenblatt R. Transderm SCOP decreases post-cesarean nausea and vomiting in patients receiving epidural morphine. *Anesthesiology* 1989;71:675-8.
  44. Koju RB, Gurung BS, Dongol Y. Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section. *BMC Anesthesiol* 2015;15:18.
  45. Kim MO, Suh KS. A comparison of the antiemetic effect of ondansetron and metoclopramide on nausea and vomiting associated with epidural buprenorphine. *Korean J Anesthesiol* 1999;37:656-61.
  46. Khaled K, Adnan AO. Comparative antiemetic efficacy of intrathecal fentanyl and intravenous metoclopramide, during caesarean section under spinal anaesthesia. 2005;17:243-7.
  47. Kasodekar S, Dhumne S, Balki M, Carvalho J, editors. Prophylactic granisetron does not prevent nausea and vomiting during elective cesarean section under spinal anesthesia. *Anesthesiology* 2006;104(Suppl 1):9.
  48. Jaafarpour M, Khani A, Dyrekvandmoghadam A, Khajavikhan J, Saaidpour K. The effect of dexamethasone on nausea, vomiting and pain in parturients undergoing caesarean delivery. *J Clin Diagn Res* 2008;3:854-8.
  49. Huang W. Clinical observation of using Metoclopramide to relieve dragging reaction during baby deliver in caesarean operation. *Chinese J Anaesthesiol* 1992;12:33.
  50. Hassanein A, Mahmoud E. Effect of low dose ketamine versus dexamethasone on intraoperative nausea and vomiting during cesarean section under spinal anesthesia. *Egypt J Anaesth* 2015;31:59-63.
  51. Harnett MJ, O'Rourke N, Walsh M, Carabuena JM, Segal S. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery. *Anesth Analg* 2007;105:764-9.
  52. Habib AS, George RB, McKeen DM, White WD, Ituk US, Megalla SA, *et al.* Antiemetics added to phenylephrine infusion during cesarean delivery: A randomized controlled trial. *Obstet Gynecol* 2013;121:615-23.
  53. Garcia-Miguel F, Montano E, Vincenti V, Fuentes A, Alsina F, San Jose J. Prophylaxis against intraoperative nausea and vomiting during spinal anesthesia for cesarean section: A comparative study of ondansetron versus metoclopramide. *Intern J Anesthesiol* 2000;4:2.
  54. El-Deeb AM, Ahmady MS. Effect of acupuncture on nausea and/or vomiting during and after cesarean section in comparison with ondansetron. *J Anesth* 2011;25:698-703.
  55. Apiliogullari S, Gök F, Canpolat A, Soysal S, Toy H. Comparison of prophylactic dimenhydrinate and metoclopramide for prevention of nausea-vomiting caused by intrathecal opioids in parturients undergoing caesarean delivery. *Reg Anesth Pain Med* 2008;33(Suppl 1):e131-e.
  56. Direkvand-Moghadam A, Khosravi A. Effect of acupressure on post-operative nausea and vomiting in cesarean section: A randomised controlled trial. *J Clin Diagn Res* 2013;7:2247-9.
  57. Dasgupta M, Biswas BN, Chatterjee S, Mazumder P, Bhanja Chowdhury M. Randomized, placebo-controlled trial of granisetron for control of nausea and vomiting during cesarean delivery under spinal anesthesia. *J Obstet Gynaecol India* 2012;62:419-23.
  58. Chestnut D, Bates J, Choi W, Vandewalker G. Administration of metoclopramide for prevention of nausea and vomiting during regional anesthesia for cesarean section: A randomized, double blind, placebo controlled study. *Anesthesiology* 1986;65:390.
  59. Cherian V, Smith I. Prophylactic ondansetron does not improve patient satisfaction in women using PCA after Caesarean section. *Br J Anaesth* 2001;87:502-4.
  60. Charuluxananan S, Kyokong O, Somboonviboon W, Narasethakamol A, Promlok P. Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery. *Anesth Analg* 2003;96:1789-93.
  61. Catling CJ, Medley N, Foureur M, Ryan C, Leap N, Teate A, *et al.* Group versus conventional antenatal care for women. *Cochrane Database Syst Rev* 2015;2015:CD007622.
  62. Cardoso MM, Leite AO, Santos EA, Gozzani JL, Mathias LA. Effect of dexamethasone on prevention of postoperative nausea, vomiting and pain after caesarean section: A randomised,

- placebo-controlled, double-blind trial. *Eur J Anaesthesiol* 2013;30:102-5.
63. Caba F, Echevarria M, Bernal-Davalos L, Pallares-Gonzalez J, Rodriguez-Rodriguez R. Prophylaxis of intraoperative nausea and vomiting with sub-hypnotic dose of propofol during intradural anesthesia in cesarean section. *Rev Espan Anesthesiol Reanim* 1997;44:262-6.
  64. Biswas B, Rudra A, Das S, Nath S, Biswas S. A comparative study of glycopyrrolate, dexamethasone and metoclopramide in control of post-operative nausea and vomiting after spinal anaesthesia for caesarean delivery. *Indian J Anaesth* 2003;47:198-200.
  65. Baciarello M, Cornini A, Zasa M, Pedrona P, Scrofani G, Venuti F, *et al.* Intrathecal atropine to prevent postoperative nausea and vomiting after Cesarean section: A randomized, controlled trial. *Minerva anesthesiol* 2011;77:781-8.
  66. Apiliogullari S, Duman A, Gok F. Prophylactic Dimenhydrinate (Dramamine) is Effective in the Treatment of Nausea-vomiting with Intrathecal Morphine. *BMJ Publishing Group Ltd*; 2007.
  67. Abouleish E, Rashid S, Haque S, Giezentanner A, Joynton P, Chuang A. Ondansetron versus placebo for the control of nausea and vomiting during Cesarean section under spinal anaesthesia. *Anaesthesia* 1999;54:479-82.
  68. Abdollahpour A, Azadi R, Bandari R, Mirmohammadkhani M. Effects of adding midazolam and sufentanil to intrathecal bupivacaine on analgesia quality and postoperative complications in elective cesarean section. *Anesthesiol Pain Med* 2015;5:e23565.
  69. Abdel-Aleem M, Osman A, Morsy K. Effect of coadministration of dexamethasone with intrathecal morphine on postoperative outcomes after cesarean delivery. *Int J Gynecol Obstet* 2012;116:158-61.
  70. Griffiths JD, Gyte GM, Paranjothy S, Brown HC, Broughton HK, Thomas J. Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section. *Cochrane Database Syst Rev* 2012;2012:CD007579.
  71. Wangmin Y-R, Yangfan L, Tonglong-Xia H. Dexamethasone for prophylaxis of nausea and vomiting after epidural opioids for post-cesarean analgesia: A meta-analysis. *Chinese J Evid Based Med* 2000;16:933-8.
  72. Salanti G, Higgins JP, Ades A, Ioannidis JP. Evaluation of networks of randomized trials. *Stat Methods Med Res* 2008;17:279-301.
  73. Gan TJ. Postoperative nausea and vomiting—can it be eliminated? *JAMA* 2002;287:1233-6.
  74. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, *et al.* Consensus guidelines for the management of postoperative nausea and vomiting. *Anesth Analg* 2014;118:85-113.
  75. Bradley EH, Curry LA, Devers KJ. Qualitative data analysis for health services research: Developing taxonomy, themes, and theory. *Health Serv Res* 2007;42:1758-72.

**Comparative efficacy of different classes of antiemetic medications for the prevention of nausea and vomiting in cesarean section: a network meta-analysis**

**Supplementary File**

Supplementary Table 1: Search Strategy

<b>Data source: MEDLINE</b>	
1	Delivery, Obstetric/
2	exp Cesarean Section/
3	exp Extraction, Obstetrical/
4	Obstetrical Forceps/
5	("c section*" or c-section* or cesar* or caesar* or delivery mode or delivery modes or elective cs or "mode of delivery" or obstetric* forcep* or planned cs* or ventouse*).ti,ab,kf
<b>6</b>	<b>1 OR 2 OR 3 OR 4 OR 5</b>
7	exp "Postoperative Nausea and Vomiting"
8	exp Anesthesia Recovery Period
9	postoperative adj3 (care or nausea or vomit*).mp.
10	(recovery adj3 (room or an?esthesia or period)).mp
11	PONV
<b>12</b>	<b>7 OR 8 OR 9 OR 10 OR 11</b>
13	(randomized controlled trial).pt
14	(controlled clinical trial).pt
15	randomized.ab
16	clinical trials as topic.sh
17	placebo.ab
18	randomly.ab
<b>21</b>	<b>13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20</b>
<b>22</b>	<b>6 AND 12 AND 21</b>

**Supplementary Table 2: characteristics of included studies**

study	country	anesthesia	surgery duration (min)	mean age (yrs)	outcome	drug1	No. of patients in group 1	No. of events in group 1	drug2	No. of patients in group 2	No. of events in group 2	drug3	No. of patients in group 3	No. of events in group 3	drug4	No. of patients in group 4	No. of events in group 4	
Abdel-Aleem 2012	Egypt	Spinal		24.9	Nausea postoperatively	Corticoids- Dexamethasone - 8 mg	60	25	Placebo	60	48							
Abdel-Aleem 2012	Egypt	Spinal		24.9	Vomiting (and/or retching) postoperatively	Corticoids- Dexamethasone - 8 mg	60	16	Placebo	60	32							
Abdollahpour 2015	Iran	Spinal		28.3	Nausea postoperatively	Sedatives- Midazolam - 0.2 mg/kg	25	3	Placebo	25	8							
Abdollahpour 2012	Iran	Spinal		28.3	Vomiting (and/or retching) postoperatively	Sedatives- Midazolam - 0.2 mg/kg	25	1	Placebo	25	5							
Abouleish 1999	UK	Spinal	47.5	26.7	Nausea intraoperatively	5-HT3- Ondansetron - 4 mg	36	21	Placebo	38	30							
Abouleish 1999	UK	Spinal	47.5	26.7	Vomiting (and/or retching) intraoperatively	5-HT3- Ondansetron - 4 mg	36	13	Placebo	38	22							
Apilogullari 2007	Turkey	unclear			Nausea postoperatively	D2- Metoclopramide - 10 mg	58	11	Placebo	63	20		Antihist- Dimenhydratate - 50 mg	62	8	Anthist- Dimenhydratate - 100 mg	60	3
Apilogullari 2007	Turkey	unclear			Vomiting (and/or retching) postoperatively	D2- Metoclopramide - 10 mg	58	13	Placebo	63	10							
Baciarello 2011	Italy	Spinal		34.3	N+V Postoperatively	Antichol- Atropine - 100 mcg	139	34	Placebo	65	33							
Biswas 2003	India	Spinal	67.2	24.2	Nausea intraoperatively	D2- Metoclopramide - 10 mg	20	4	Placebo	20	8		Corticoids- Dexamethasone - 8 mg	20	2	Antichol- Glycopyrrolate - 0.2 mg	20	2
Biswas 2003	India	Spinal	67.2	24.2	Vomiting (and/or retching) intraoperatively	D2- Metoclopramide - 10 mg	20	2	Placebo	20	3		Corticoids- Dexamethasone - 8 mg	20	2	Antichol- Glycopyrrolate - 0.2 mg	20	1
Caba 1997	Spain	Intradural			Nausea intraoperatively	Sedatives- Propofol - 10 mg	26	5	Placebo	31	5							
Caba 1997	Spain	Intradural			Vomiting (and/or retching) intraoperatively	Sedatives- Propofol - 10 mg	26	1	Placebo	31	2							
Caba 1997	Spain	Intradural			Nausea postoperatively	Sedatives- Propofol - 10 mg	26	2	Placebo	31	1							





Harnett 2007	USA	Spinal							80	15	81	9	79	16		
			Vomiting (and/or retching) intraoperatively	Antichol- Scopolamine patch							Placebo					
Harnett 2007	USA	Spinal							80	32	81	59	79	33		
			Vomiting (and/or retching) postoperatively	Antichol- Scopolamine patch							Placebo					
Hassanein 2015	Egypt	Spinal	29.3	53.6					45	8	45	13	45	6		
			Nausea intraoperatively	Corticoids- Dexamethasone - 8 mg							Placebo					
Hassanein 2015	Egypt	Spinal	29.3	53.6					45	5	45	9	45	4		
			Vomiting (and/or retching) intraoperatively	Corticoids- Dexamethasone - 8 mg							Placebo					
Huang 1992		Regional							50	4	50	15				
			Nausea intraoperatively	D2- Metoclopramide - 20 mg							Placebo					
Jaafarpour 2008	Iran	Spinal							40	2	40	7				
			Nausea intraoperatively	Corticoids- Dexamethasone - 8 mg							Placebo					
Jaafarpour 2008	Iran	Spinal							40	1	40	8				
			Vomiting (and/or retching) intraoperatively	Corticoids- Dexamethasone - 8 mg							Placebo					
Kasodekar 2006	Egypt	Spinal							88	16	88	14				
			Nausea intraoperatively	5-HT3- Granisetron - 1 mg							Placebo					
Kasodekar 2006	Egypt	Spinal							88	4	88	6				
			Vomiting (and/or retching) intraoperatively	5-HT3- Granisetron - 1 mg							Placebo					
Khalayleh 2005	Iran	Spinal							48	3	50	21				
			Nausea intraoperatively	D2- Metoclopramide - 10 mg							Placebo					
Kim 1999	South Korea	epidural							20	1	20	0				
			Nausea intraoperatively	D2- Metoclopramide - 10 mg							Placebo					
Koju 2015	Nepal	Spinal							25	2	25	14				
			Nausea postoperatively	5-HT3- Ondansetron - 4 mg							Placebo					
Kotelko 1989	USA	epidural							102	43	101	71				
			Nausea intraoperatively	Antichol- Scopolamine patch							Placebo					
Kotelko 1989	USA	epidural							102	33	101	53				
			Vomiting (and/or retching) intraoperatively	Antichol- Scopolamine patch							Placebo					
Lussos 1992	USA	Spinal							21	0	21	12				
			Nausea intraoperatively	D2- Metoclopramide - 10 mg							Placebo					











Jabalameili 2012	Iran	Spinal	65.3	29.6	Vomiting (and/or retching) postoperatively	Sedatives- Midazolam 30 µg/kg	44	16	5-HT3- Ondansetron - 8 mg	44	15							
Jabalameili 2012	Iran	Spinal	65.3	29.6	Nausea postoperatively	Sedatives- Midazolam 30 µg/kg	44	18	5-HT3- Ondansetron - 8 mg	44	20							
Jabalameili 2012	Iran	Spinal	65.3	29.6	Nausea intraoperatively	Sedatives- Midazolam 30 µg/kg	44	32	5-HT3- Ondansetron - 8 mg	44	27							
Jabalameili 2012	Iran	Spinal	65.3	29.6	Vomiting (and/or retching) intraoperatively	Sedatives- Midazolam 30 µg/kg	44	30	5-HT3- Ondansetron - 8 mg	44	32							
Jain 2015	India	Spinal		30.4	Nausea intraoperatively	5-HT3- Ondansetron n - 4 mg	32	15	Antichol- Glycopyrrolate - 0.2 mg	31	13							
Jain 2015	India	Spinal		30.4	Vomiting (and/or retching) intraoperatively	5-HT3- Ondansetron n - 4 mg	32	5	Antichol- Glycopyrrolate - 0.2 mg	31	6							
Jain 2015	India	Spinal		30.4	Nausea postoperatively	5-HT3- Ondansetron n - 4 mg	32	4	Antichol- Glycopyrrolate - 0.2 mg	31	5							
Jain 2015	India	Spinal		30.4	Vomiting (and/or retching) postoperatively	5-HT3- Ondansetron n - 4 mg	32	1	Antichol- Glycopyrrolate - 0.2 mg	31	2							

Supplementary Table 3: Q statistic to assess consistency under the assumption of a full design-by-treatment interaction random effects model:

	Q	d.f.	P value
Between-designs	7.9	17	0.96
<b>1. intraoperative nausea</b>			
	Q	d.f.	P value
Between-designs	14.7	17	0.61
<b>2. intraoperative vomiting</b>			
	Q	d.f.	P value
Between-designs	5.6	10	0.84
<b>3. postoperative nausea</b>			
	Q	d.f.	P value
Between-designs	8.4	14.0	0.86
<b>4. postoperative vomiting</b>			

Supplementary Table 4: Results of direct, indirect, and network meta-analyses

Supplementary Table 4-1 Results of *network* on intraoperative nausea

Comparisons	Number of RCTs	Direct Evidence proportion	NMA	OR derived from direct evidence	OR derived from indirect evidence	Ratio of Ratios	p-value
5HT3 vs Anticholinergic agents	2	0.49	0.95	1.00	0.91	1.09	0.87
5HT3 vs Antihistamines	0	0.00	0.32	.	0.32	.	.
5HT3 vs Corticosteroids	1	0.32	0.76	0.58	0.86	0.64	0.52
5HT3 vs Dopamine receptor antagonists	3	0.30	1.16	0.72	1.42	0.51	0.19
5HT3 vs Placebo	12	0.83	0.31	0.35	0.19	1.76	0.21
5HT3 vs Sedatives	1	0.19	0.72	0.59	0.76	0.78	0.72
Anticholinergic agents vs Antihistamines	0	0.00	0.33	.	0.33	.	.
Anticholinergic agents vs Corticosteroids	1	0.10	0.79	1.00	0.77	1.29	0.83
Anticholinergic agents vs Dopamine receptor antagonists	1	0.10	1.21	0.44	1.35	0.32	0.29
Anticholinergic agents vs Placebo	4	0.77	0.33	0.37	0.23	1.59	0.46
Anticholinergic agents vs Sedatives	0	0.00	0.75	.	0.75	.	.
Antihistamines vs Corticosteroids	0	0.00	2.36	.	2.36	.	.
Antihistamines vs Dopamine receptor antagonists	0	0.00	3.61	.	3.61	.	.
Antihistamines vs Placebo	1	1.00	0.99	0.99	.	.	.
Antihistamines vs Sedatives	0	0.00	2.25	.	2.25	.	.
Corticosteroids vs Dopamine receptor antagonists	2	0.23	1.52	0.62	1.99	0.31	0.11
Corticosteroids vs Placebo	6	0.87	0.41	0.42	0.35	1.21	0.80
Corticosteroids vs Sedatives	1	0.22	0.95	1.40	0.85	1.63	0.54
<b>Dopamine receptor antagonists vs Placebo</b>	<b>15</b>	<b>0.92</b>	<b>0.27</b>	<b>0.24</b>	<b>1.00</b>	<b>0.24</b>	<b>0.04</b>
Dopamine receptor antagonists vs Sedatives	1	0.16	0.62	0.70	0.60	1.16	0.84
Sedatives vs Placebo	8	0.81	0.43	0.44	0.41	1.07	0.90

**Supplementary Table 4-2 Results of *netplit* on intraoperative vomiting**

Comparisons	Number of RCTs	Direct Evidence proportion	NMA	OR derived from direct evidence	OR derived from indirect evidence	Ratio of Ratios	p-value
5HT3 vs Anticholinergic agents	2	0.50	0.70	0.97	0.51	1.89	0.30
5HT3 vs Antihistamines	0	0.00	0.38	.	0.38	.	.
5HT3 vs Corticosteroids	1	0.20	0.78	0.41	0.92	0.44	0.35
5HT3 vs Dopamine receptor antagonists	3	0.28	1.03	0.65	1.22	0.53	0.34
5HT3 vs Placebo	11	0.82	0.34	0.38	0.22	1.69	0.30
5HT3 vs Sedatives	1	0.25	1.41	1.24	1.48	0.84	0.79
Anticholinergic agents vs Antihistamines	0	0.00	0.54	.	0.54	.	.
Anticholinergic agents vs Corticosteroids	1	0.10	1.11	0.47	1.22	0.38	0.49
Anticholinergic agents vs Dopamine receptor antagonists	1	0.08	1.45	0.47	1.60	0.29	0.37
<b>Anticholinergic agents vs Placebo</b>	<b>4</b>	<b>0.78</b>	<b>0.49</b>	<b>0.67</b>	<b>0.15</b>	<b>4.29</b>	<b>0.03</b>
Anticholinergic agents vs Sedatives	0	0.00	1.99	.	1.99	.	.
Antihistamines vs Corticosteroids	0	0.00	2.05	.	2.05	.	.
Antihistamines vs Dopamine receptor antagonists	0	0.00	2.69	.	2.69	.	.
Antihistamines vs Placebo	1	1.00	0.91	0.91	.	.	.
Antihistamines vs Sedatives	0	0.00	3.69	.	3.69	.	.
Corticosteroids vs Dopamine receptor antagonists	2	0.29	1.31	1.00	1.46	0.68	0.65
Corticosteroids vs Placebo	6	0.89	0.44	0.45	0.38	1.17	0.87
Corticosteroids vs Sedatives	1	0.24	1.80	1.28	2.0	0.63	0.62
Dopamine receptor antagonists vs Placebo	12	0.93	0.33	0.31	0.86	0.36	0.29
Dopamine receptor antagonists vs Sedatives	1	0.13	1.37	2.89	1.23	0.83	0.40
Sedatives vs Placebo	8	0.81	0.24	0.24	0.25	0.95	0.94


**Supplementary Table 4-3 Results of *netplit* on postoperative nausea**

Comparisons	Number of RCTs	Direct Evidence proportion	NMA	OR derived from direct evidence	OR derived from indirect evidence	Ratio of Ratios	p-value
5HT3 vs Anticholinergic agents	1	1.00	0.74	0.74	.	.	.
5HT3 vs Antihistamines	0	0.00	1.00	0.00	1.00	.	.
5HT3 vs Corticosteroids	1	0.26	0.72	1.00	0.64	1.55	0.55
5HT3 vs Dopamine receptor antagonists	2	0.36	0.57	0.45	0.65	0.70	0.59
5HT3 vs Opioid antagonist	1	0.79	0.44	0.52	0.22	2.31	0.56
5HT3 vs Placebo	10	0.87	0.25	0.27	0.15	1.71	0.40
5HT3 vs Sedatives	1	0.46	1.53	1.20	1.87	0.64	0.62
Anticholinergic agents vs Antihistamines	0	0.00	1.35	.	1.35	.	.
Anticholinergic agents vs Corticosteroids	0	0.00	0.97	.	0.97	.	.
Anticholinergic agents vs Dopamine receptor antagonists	0	0.00	0.76	.	0.76	.	.
Anticholinergic agents vs Opioid antagonist	0	0.00	0.59	.	0.59	.	.
Anticholinergic agents vs Placebo	0	0.00	0.34	.	0.34	.	.
Anticholinergic agents vs Sedatives	0	0.00	2.06	.	2.06	.	.
Antihistamines vs Corticosteroids	1	0.29	0.71	0.33	0.97	0.34	0.22
Antihistamines vs Dopamine receptor antagonists	2	0.56	0.56	0.44	0.77	0.56	0.46
Antihistamines vs Opioid antagonist	0	0.00	0.43	.	0.43	.	.
Antihistamines vs Placebo	4	0.87	0.25	0.29	0.07	3.80	0.17
Antihistamines vs Sedatives	0	0.00	1.51	.	1.51	.	.
Corticosteroids vs Dopamine receptor antagonists	0	0.00	0.79	.	0.79	.	.
Corticosteroids vs Opioid antagonist	0	0.00	0.61	.	0.61	.	.
Corticosteroids vs Placebo	6	0.93	0.35	0.35	0.30	1.19	0.86
Corticosteroids vs Sedatives	0	0.00	2.12	.	2.12	.	.
Dopamine receptor antagonists vs Opioid antagonist	0	0.00	0.77	.	0.77	.	.
Dopamine receptor antagonists vs Placebo	7	0.89	0.44	0.43	0.59	0.72	0.70
Dopamine receptor antagonists vs Sedatives	0	0.00	2.68	.	2.68	.	.
Opioid antagonist vs Placebo	1	0.78	0.57	0.68	0.29	2.29	0.56
Opioid antagonist vs Sedatives	0	0.00	3.45	.	3.45	.	.
Sedatives vs Placebo	3	0.60	0.16	0.13	0.21	0.64	0.62



**Supplementary Table 4-4 Results of *netplit* on postoperative vomiting**

Comparisons	Number of RCTs	Direct Evidence proportion	NMA	OR derived from direct evidence	OR derived from indirect evidence	Ratio of Ratios	p-value
5HT3 vs Anticholinergic agents	2	0.83	0.99	0.92	1.38	0.67	0.77
5HT3 vs Antihistamines	0	0.00	1.26	.	1.26	.	.
5HT3 vs Corticosteroids	1	0.03	0.53	1.00	0.53	1.89	0.76
5HT3 vs Dopamine receptor antagonists	2	0.26	0.56	0.52	0.57	0.91	0.90
5HT3 vs Opioid antagonist	1	0.83	0.43	0.68	0.04	14.38	0.17
5HT3 vs Placebo	10	0.90	0.29	0.32	0.10	3.06	0.19
5HT3 vs Sedatives	1	0.54	2.21	0.90	3.25	0.14	0.06
Anticholinergic agents vs Antihistamines	0	0.00	1.26	.	1.26	.	.
Anticholinergic agents vs Corticosteroids	0	0.00	0.54	.	0.54	.	.
Anticholinergic agents vs Dopamine receptor antagonists	0	0.00	0.56	.	0.56	.	.
Anticholinergic agents vs Opioid antagonist	0	0.00	0.43	.	0.43	.	.
Anticholinergic agents vs Placebo	1	0.69	0.29	0.24	0.43	0.57	0.63
Anticholinergic agents vs Sedatives	0	0.00	2.22	.	2.22	.	.
Antihistamines vs Corticosteroids	1	0.44	0.42	0.32	0.52	0.62	0.64
Antihistamines vs Dopamine receptor antagonists	1	0.42	0.44	0.30	0.57	0.53	0.54
Antihistamines vs Opioid antagonist	0	0.00	0.34	.	0.34	.	.
Antihistamines vs Placebo	3	0.82	0.23	0.32	0.05	6.42	0.13
Antihistamines vs Sedatives	0	0.00	1.75	.	1.75	.	.
Corticosteroids vs Dopamine receptor antagonists	1	0.22	1.04	1.78	0.90	1.97	0.43
Corticosteroids vs Opioid antagonist	0	0.00	0.80	.	0.80	.	.
Corticosteroids vs Placebo	7	0.94	0.54	0.52	1.03	0.50	0.57
Corticosteroids vs Sedatives	0	0.00	4.10	.	4.10	.	.
Dopamine receptor antagonists vs Opioid antagonist	0	0.00	0.76	.	0.76	.	.
Dopamine receptor antagonists vs Placebo	9	0.93	0.52	0.53	0.35	1.48	0.68
Dopamine receptor antagonists vs Sedatives	0	0.00	3.93	.	3.93	.	.
Opioid antagonist vs Placebo	1	0.72	0.67	1.27	0.13	9.58	0.17
Opioid antagonist vs Sedatives	0	0.00	5.11	.	5.11	.	.
Sedatives vs Placebo	3	0.53	0.13	0.05	0.36	0.14	0.06



**Supplementary fig 1: Risk of bias summary (Traffic light).**